Evidence map›Paper›PMID 28126968›Full record

ArticleHaematologica2017

CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27

Feifei Zhang, Xiaoye Liu, Chiqi Chen, Jun Zhu, Zhuo Yu, Jingjing Xie, Li Xie, Haitao Bai, Yaping Zhang, Xia Fang and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Immunotherapy in leukaemia.Acta biochimica et biophysica Sinica · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Feifei ZhangHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Xiaoye LiuHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Chiqi ChenHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Jun ZhuDepartment of Hematology, The 1 People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Zhuo YuHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Jingjing XieBinzhou Medical University, Taishan Scholar Immunology Program, Yantai, China.
Li XieHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Haitao BaiDepartment of Hematology, The 1 People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Yaping ZhangHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Xia FangDepartment of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai, China.
Hao GuHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Chun WangDepartment of Hematology, The 1 People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Wei WengHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China.
Cheng Cheng ZhangDepartments of Physiology and Developmental Biology, UT Southwestern Medical Center, Dallas, TX, USA.
Guo-Qiang ChenHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China chengq@shsmu.edu.cn zhengjunke@shsmu.edu.cn lab7182@tongji.edu.cn.
Aibing LiangDepartment of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai, China chengq@shsmu.edu.cn zhengjunke@shsmu.edu.cn lab7182@tongji.edu.cn.
Junke ZhengHongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, China chengq@shsmu.edu.cn zhengjunke@shsmu.edu.cn lab7182@tongji.edu.cn.
Shanghai Jiao Tong University · CNTongren Hospital · CNTongji Hospital · CNBinzhou University · CNThe University of Texas Southwestern Medical Center · US

Funding

The role of inhibitory receptors in leukemia developmentR01CA172268 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, CHENGCHENG · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA172268
6 · The paper itself

Abstract

Targeting leukemia initiating cells is considered to be an effective way to cure leukemia, for which it is critical to identify novel therapeutic targets. Herein, we demonstrate that CD244, which was initially reported as a key regulator for natural killer cells, is highly expressed on both mouse and human leukemia initiating cells. Upon CD244 knockdown, human leukemia cell lines and primary leukemia cells have markedly impaired proliferation abilities both

Indexed as

Signal TransductionAnimalsBiomarkersCell Line, TumorCell ProliferationCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p27Disease Models, AnimalHumansImmunophenotypingLeukemiaMiceMice, KnockoutModels, BiologicalNeoplastic Stem CellsPhenotypeBiomarkersCD244 protein, humanCyclin-Dependent Kinase Inhibitor p27Protein Tyrosine Phosphatase, Non-Receptor Type 11Signaling Lymphocytic Activation Molecule Family

Identifiers

PMID28126968
PMCPMC5395111
OpenAlexW2580728147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.